Back to Search
ANDRE GOY, MD
MD
Medical Oncology Physician
NPI: 1215992912IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
25MA07761300(NJ)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
25MA07761300(NJ)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1988
Research & Publications (20)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
PMID 19074748·Ann Oncol·2009
3-trial
Expanding therapeutic options in mantle cell lymphoma.
PMID 17877843·Clin Lymphoma Myeloma·2007
6-review
New directions in the treatment of mantle cell lymphoma: an overview.
PMID 17101070·Clin Lymphoma Myeloma·2006
6-review
Informatics-guided procurement of patient samples for biomarker discovery projects in cancer research.
PMID 19016349·Cell Tissue Bank·2009
8-other
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
PMID 18085611·Cancer·2008
3-trial
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
PMID 17608763·Br J Haematol·2007
3-trial
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
PMID 17233846·Br J Haematol·2007
3-trial
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
PMID 17054068·J Infect Dis·2006
2-rct
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
PMID 17008093·Eur J Cancer·2006
8-other
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
PMID 17001068·J Clin Oncol·2006
3-trial
Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
PMID 16882131·Br J Haematol·2006
3-trial
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
PMID 16396772·Leuk Lymphoma·2006
3-trial
The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma.
PMID 16329118·Cancer·2006
8-other
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
PMID 16145068·J Clin Oncol·2005
3-trial
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
PMID 15806128·Bone Marrow Transplant·2005
8-other
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
PMID 15613697·J Clin Oncol·2005
3-trial
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
PMID 15353540·J Clin Oncol·2004
3-trial
Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.
PMID 15385932·Leukemia·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 92 2ND ST
HACKENSACK, NJ 07601 - Phone
- (551) 996-3033
Quick Facts
- NPI
- 1215992912
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 38
- Publications
- 20
Are you this provider?
Claim Your Profile